Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2011, Article ID 710216, 2 pages
http://dx.doi.org/10.1155/2011/710216
Case Report

Development of Nephrotic Syndrome after Administration of Sorafenib in a Case of Metastatic Renal Cell Carcinoma

Department of Urology, The University of Tokyo Hospital, Tokyo 113-8655, Japan

Received 7 July 2011; Accepted 9 August 2011

Academic Editor: W. Zidek

Copyright © 2011 Yumiko Okuno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. C. Huang, A. S. Levey, A. M. Serio et al., “Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study,” The Lancet Oncology, vol. 7, no. 9, pp. 735–740, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. J. McKiernan, R. Simmons, J. Katz, and P. Russo, “Natural history of chronic renal insufficiency after partial and radical nephrectomy,” Urology, vol. 59, no. 6, pp. 816–820, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. E. J. Rolleman, J. Weening, and M. G. H. Betjes, “Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma,” Nephrology Dialysis Transplantation, vol. 24, no. 6, pp. 2002–2003, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. E. N. Overkleeft, R. Goldschmeding, F. van Reekum, E. E. Voest, and H. M. Verheul, “Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib,” Annals of Oncology, vol. 21, no. 1, pp. 184–185, 2010. View at Google Scholar · View at Scopus
  5. S. K. Winn, S. Ellis, P. Savage, S. Sampson, and J. E. Marsh, “Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?” Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 673–675, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. T. V. Patel, J. A. Morgan, G. D. Demetri et al., “A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib,” Journal of the National Cancer Institute, vol. 100, no. 4, pp. 282–284, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. Y. S. Chen, C. L. Chen, and J. S. Wang, “Nephrotic syndrome and acute renal failure apparently induced by sunitinib,” Case Reports in Oncology, vol. 2, pp. 172–176, 2009. View at Google Scholar
  8. I. J. Jonkers and M. van Buren, “Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma,” Clinical and Experimental Nephrology, vol. 13, no. 4, pp. 397–401, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. O. Costero, M. L. Picazo, P. Zamora, S. Romero, J. Martinez-Ara, and R. Selgas, “Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy,” Nephrology Dialysis Transplantation, vol. 25, no. 3, pp. 1001–1003, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. S. Wu, C. Kim, L. Baer, and X. Zhu, “Bevacizumab increases risk for severe proteinuria in cancer patients,” Journal of the American Society of Nephrology, vol. 21, no. 8, pp. 1381–1389, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus